amcure GmbH is a spin-off from the Karlsruhe Institute of Technology established in 2011. The company develops peptide-based compounds for the treatment of highly metastatic forms of cancer. amcure’s most advanced development candidate, AMC303, has entered clinical development and has demonstrated in in vivo proof-of-concept studies a high efficacy against different types of epithelial cancers. amcure is sponsored by a grant from the German Federal Ministry of Education and Research.
CEO: Klaus Dembowsky
COO and CFO: Matthias Klaften
CSO: Alexandra Matzke
Please click here for amcure job opportunities.